ALX Oncology Reports Director/Officer Changes
Ticker: ALXO · Form: 8-K · Filed: Aug 6, 2024 · CIK: 1810182
Sentiment: neutral
Topics: corporate-governance, officer-changes, compensation
Related Tickers: ALXO
TL;DR
ALXO board shakeup, new officers appointed, and comp details filed.
AI Summary
ALX Oncology Holdings Inc. filed an 8-K on August 5, 2024, reporting changes in its board of directors and certain officers, along with updates on compensatory arrangements. The filing also includes information on other events and financial statements/exhibits, indicating potential corporate governance shifts and operational updates for the company.
Why It Matters
Changes in board and officer composition can signal shifts in company strategy, governance, or operational focus, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and officer compensation can introduce uncertainty regarding future strategy and execution.
Key Numbers
- 001-39386 — Commission File Number (Identifies the company's SEC filing history.)
- 85-0642577 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- ALX Oncology Holdings Inc. (company) — Registrant
- Delaware (jurisdiction) — State of Incorporation
- South San Francisco, California (location) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors or certain officers?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' under Item 5.02, but the specific names and details of these changes are not provided in this excerpt.
What is the nature of the 'Compensatory Arrangements' mentioned?
The filing notes 'Compensatory Arrangements of Certain Officers' under Item 5.02, suggesting updates or new information regarding executive compensation, though specifics are not detailed here.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on August 5, 2024.
What is the primary business of ALX Oncology Holdings Inc. according to the filing?
ALX Oncology Holdings Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
Where are ALX Oncology Holdings Inc.'s principal executive offices located?
The principal executive offices are located at 323 Allerton Avenue, South San Francisco, California 94080.
Filing Stats: 1,242 words · 5 min read · ~4 pages · Grade level 11.1 · Accepted 2024-08-06 16:45:02
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ALXO The Nasdaq Global Se
Filing Documents
- alxo-20240805.htm (8-K) — 57KB
- alxo-ex99_1.htm (EX-99.1) — 19KB
- img62044099_0.jpg (GRAPHIC) — 149KB
- 0000950170-24-091938.txt ( ) — 392KB
- alxo-20240805.xsd (EX-101.SCH) — 25KB
- alxo-20240805_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. As previously disclosed in connection with prior Board composition changes in April 2024, the Company notified Nasdaq that the Company was not in compliance with Nasdaq Listing Rule 5605(a)(2) regarding having a majority of independent directors on the Board subject to the automatic 180 day period within which to restore the majority of independent directors. Following the Board changes referenced above, the Board currently consists of five directors of which four are considered independent directors, which resolves any non-compliance with Nasdaq Listing Rule 5605(a)(2). 1 Effective as of August 5, 2024 in connection with the Board changes referenced above, the Board approved the following composition of committees of the Board: Audit Committee Rekha Hemrajani, Chair; Scott Garland; and Alan Sandler, M.D. Compensation Committee Corey Goodman, Ph.D., Chair; Scott Garland; and Alan Sandler, M.D. Corporate Governance and Nominating Committee Scott Garland, Chair; Corey Goodman, Ph.D.; and Rekha Hemrajani
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated August 6, 2024 104 Cover Page Interactive Data File (formatted as Inline XBRL) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ALX ONCOLOGY HOLDINGS INC. Date: August 6, 2024 By: /s/ Peter Garcia Peter Garcia Chief Financial Officer 3